{"createdAt":"8/2/2020, 1:45:10 PM","timestamp":1596390310490,"Company ID number":"156","DMX_ISSUER_NAME":"Sichuan Hebang Biotechnology Co., Ltd.","DMX_ISSUER_ID":"IID000000002649145","Country of Classification":"CHINA","name":"Sichuan Hebang Biotechnology Co Ltd ","code":"603077","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"四川和邦生物科技股份有限公司_曾小平","group":"board","name":"曾小平","title":"董事长,董事","isMale":true,"age":"59","degree":"硕士","salary":"57.13万","stockAmount":"-","description":"曾小平:男,汉族,1961年生,中国籍,无永久境外居住权,长江商学院EMBA。曾就职于乐山市市中区人民法院、四川乐山振静皮革制品有限公司、乐山市五通桥区华强投资有限公司。2016年4月至今任和邦集团总裁,2016年11月至今任振静股份董事,2016年5月至2017年5月任公司副董事长,2017年5月至今任四川和邦生物科技股份有限公司董事长。","lastUpdated":"2020-05-16"},{"id":"四川和邦生物科技股份有限公司_莫融","group":"board","name":"莫融","title":"董事","isMale":true,"age":"48","degree":"本科","salary":"38.94万","stockAmount":"294.2万","description":"莫融:男,汉族,1972年生,中国籍,无永久境外居住权,本科学历。1996年至2001年为四川天闻律师事务所律师,2001年至2007年为四川兴精诚律师事务所律师。2008年2月至今任四川和邦生物科技股份有限公司董事、董事会秘书。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_王军","group":"board","name":"王军","title":"董事","isMale":true,"age":"49","degree":"本科","salary":"28.09万","stockAmount":"294.2万","description":"王军:男,汉族,1971年生,中国籍,无永久境外居住权,本科学历,高级会计师、注册会计师、注册税务师。1991年至2003年在乐山市糖酒副食品总公司工作,2003年2月至2008年1月任和邦盐化副总经理、财务总监。2008年2月至今任四川和邦生物科技股份有限公司董事、副总经理兼财务总监。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_贺正刚","group":"board","name":"贺正刚","title":"董事","isMale":true,"age":"66","degree":"硕士","salary":"87.82万","stockAmount":"4.126亿","description":"贺正刚:男,汉族,1954年生,中国籍,无永久境外居住权,EMBA学历。1971年至1992年就职于乐山市商业局,1993年至今任四川和邦投资集团有限公司(以下简称“和邦集团”)董事长,2012年8月至今任和邦集团总经理,2013年12月至今任四川振静股份有限公司(以下简称“振静股份”)董事长。2002年至2017年5月任公司董事长,2017年5月至今任四川和邦生物科技股份有限公司董事。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_宋克利","group":"board","name":"宋克利","title":"董事","isMale":true,"age":"65","degree":"大专","salary":"0.00","stockAmount":"-","description":"宋克利:男,汉族,1955年生,中国籍,无永久境外居住权,大专学历,高级会计师、注册会计师。1980年至1999年历任东方锅炉厂会计、科长、处长、副总会计师,1999年至今任和邦集团副总经理,2013年12月至今任振静股份董事,2008年2月至今任四川和邦生物科技股份有限公司董事。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_杨红武","group":"board","name":"杨红武","title":"董事","isMale":true,"age":"57","degree":"本科","salary":"6.090万","stockAmount":"289.2万","description":"杨红武:男,汉族,1963年生,中国籍,无永久境外居住权,本科学历。1982年至1991年就职于乐山市五通桥区教育局,1991年进入政法系统工作,先后在五通桥区政法委、公安局就职,后调任犍为县公安局局长,乐山市经济犯罪侦察支队队长,2008年9月辞职,2008年10月起就职于公司,2009年10月至2011年3月任公司副总经理;2011年4月至2017年5月25日任公司总经理。2013年2月至今任四川和邦生物科技股份有限公司董事。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_梅淑先","group":"board","name":"梅淑先","title":"独立董事","isMale":false,"age":"56","degree":"本科","salary":"0.00","stockAmount":"-","description":"梅淑先:女,汉族,1964年生,中国籍,无永久境外居住权,1987年7月毕业于西南财经大学会计学专业,本科学历,经济学学士,教授。1987年7月至2002年4月在乐山财贸学校任会计专业教师,2002年4月至2010年11月在乐山职业技术学院任会计专业教师,2010年11月至2017年7月在乐山职业技术学院任财经管理系副主任,同时兼任会计专业教师。2017年7月至今任乐山职业技术学院财经管理系党总支书记,同时兼任会计专业教师。2017年5月22日起至今任四川和邦生物科技股份有限公司独立董事。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_胡杨","group":"board","name":"胡杨","title":"独立董事","isMale":true,"age":"52","degree":"硕士","salary":"--","stockAmount":"-","description":"胡杨:男,汉族,1968年生,中国籍,无永久境外居住权,研究生学历,1985年12月至2006年11月就职于四川省乐山市市中区人民法院,2008年1月至2018年12月任四川四通破产清算事务有限责任公司总经理,2019年1月至今任四川四通破产清算事务有限责任公司高级法律顾问。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_袁长华","group":"board","name":"袁长华","title":"独立董事","isMale":true,"age":"62","degree":"高中","salary":"--","stockAmount":"-","description":"袁长华:男,汉族,1958年生,中国籍,无永久境外居住权,高中学历,1979年至1999年历任乐山市五通桥区食品公司金山食品站站长、冠英冷冻厂厂长,1999年至今任乐山市长益食品有限公司执行董事兼总经理。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_缪成云","group":"supervisoryCommittee","name":"缪成云","title":"监事会主席","isMale":true,"age":"57","degree":"大专","salary":"17.74万","stockAmount":"-","description":"缪成云:男,1963年生,中国籍,无永久境外居住权,大专学历,注册会计师、注册资产评估师、司法鉴定人。1982年7月至1997年就职于乐山市食品公司,其间任财务科长、副厂长等职务;1997年10月至1999年9月任洛阳春都集团夹江肉联厂财务科长、副厂长;1999年10月至2003年3月任乐山乐咨会计师事务所审计部部长,2003年4月至今任四川和邦生物科技股份有限公司审计监察部主任。2008年2月至今任四川和邦生物科技股份有限公司监事会主席。","lastUpdated":"2020-05-16"},{"id":"四川和邦生物科技股份有限公司_龚嵘鹏","group":"supervisoryCommittee","name":"龚嵘鹏","title":"职工监事","isMale":true,"age":null,"degree":"本科","salary":"10.28万","stockAmount":"-","description":"龚嵘鹏:男,汉族,中国籍,大学本科学历,统计师职称。2002年-2008年在和邦集团财务部工作。2008年-2012年任和邦集团财务部财务经理助理。2012年-2014年任乐山和邦农业科技有限公司成本部部长、总经理助理。2014年至今,任四川和邦生物科技股份有限公司成本部部长、总经理助理。2017年5月25日起至今任四川和邦生物科技股份有限公司职工监事。","lastUpdated":"2020-05-16"},{"id":"四川和邦生物科技股份有限公司_卢丹","group":"supervisoryCommittee","name":"卢丹","title":"职工监事","isMale":false,"age":null,"degree":"大专","salary":"--","stockAmount":"-","description":"卢丹:女,汉族,中国籍,大学专科学历,英语专业;1998年-2004年在四川乐山振静皮革制品有限公司工作;2004年起,在公司工作,2019年1月至今任四川和邦生物科技股份有限公司纪委办公室主任。","lastUpdated":"2020-07-23"},{"id":"四川和邦生物科技股份有限公司_杨惠容","group":"manager","name":"杨惠容","title":"总经理","isMale":false,"age":"56","degree":"大专","salary":"46.08万","stockAmount":"4.4万","description":"杨惠容:女,汉族,1964年生,中国籍,无永久境外居住权,大专学历。1992年至1995年就职于乐山皮革公司,1995年至2005年任振静皮革车间主任,2005年至今任四川和邦生物科技股份有限公司工艺纪律检查委员会主任。2011年3月至2017年5月任公司监事。2017年5月25日起至今任四川和邦生物科技股份有限公司总经理。","lastUpdated":"2020-05-16"},{"id":"四川和邦生物科技股份有限公司_莫融","group":"manager","name":"莫融","title":"董事会秘书","isMale":true,"age":"48","degree":"本科","salary":"38.94万","stockAmount":"294.2万","description":"莫融:男,汉族,1972年生,中国籍,无永久境外居住权,本科学历。1996年至2001年为四川天闻律师事务所律师,2001年至2007年为四川兴精诚律师事务所律师。2008年2月至今任四川和邦生物科技股份有限公司董事、董事会秘书。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_王军","group":"manager","name":"王军","title":"副总经理,财务总监","isMale":true,"age":"49","degree":"本科","salary":"28.09万","stockAmount":"294.2万","description":"王军:男,汉族,1971年生,中国籍,无永久境外居住权,本科学历,高级会计师、注册会计师、注册税务师。1991年至2003年在乐山市糖酒副食品总公司工作,2003年2月至2008年1月任和邦盐化副总经理、财务总监。2008年2月至今任四川和邦生物科技股份有限公司董事、副总经理兼财务总监。","lastUpdated":"2020-05-14"},{"id":"四川和邦生物科技股份有限公司_王亚西","group":"manager","name":"王亚西","title":"副总经理","isMale":true,"age":"66","degree":"大专","salary":"36.09万","stockAmount":"-","description":"王亚西:男,汉族,1954年生,中国籍,无永久境外居住权,大专学历。1982年至1987年任乐山市食品公司副经理,1997年至2004年任乐山市振静皮革制品有限公司总经理助理,2004年任和邦化工总经理。2008年2月至今任四川和邦股份有限公司董事、副总经理。","lastUpdated":"2012-07-09"},{"id":"四川和邦生物科技股份有限公司_刘安平","group":"manager","name":"刘安平","title":"副总经理","isMale":true,"age":"57","degree":"本科","salary":"15.67万","stockAmount":"-","description":"刘安平,男,1963年2月18日出生,大学学历。曾在乐山市天然气化工厂先后任技术员、车间副主任、厂长助理、生产副厂长等职;在四川和邦股份有限公司工作,先后任总厂厂长助理兼合成分厂厂长、新建20万吨/年合成氨装置部长、总厂副厂工兼合成分厂厂长。","lastUpdated":"2016-05-26"}],"companyName":"四川和邦生物科技股份有限公司","province":"四川省","englishName":"Sichuan Hebang Biotechnology Co Ltd","industry":"化工 — 化学原料","website":"www.hebang.cn","mainBusiness":"农药及农药中间体制造、精细化工产品制造、玻璃制造及纯碱、氯化铵制造及盐矿、磷矿的开发","productsName":["碳酸钠","氯化铵","双甘膦","原片玻璃","制品玻璃","镀膜玻璃","草甘膦原粉","天然杀菌剂","水产制剂"],"actualController":"贺正刚","actualControllerSharePercentage":"32.62%","registeredCapital":"88.31亿元","employeeAmount":"4813","phone":"86-028-62050230","location":"四川省乐山市五通桥区","chineseDescription":"四川和邦生物科技股份有限公司的主营业务为农药及农药中间体制造、精细化工产品制造、玻璃制造及纯碱、氯化铵制造及盐矿、磷矿的开发。主要产品有碳酸钠、氯化铵、双甘膦、原片玻璃、制品玻璃、镀膜玻璃、草甘膦原粉、天然杀菌剂、水产制剂。公司主营业务双甘膦已成为全球范围内最大的供应商，全球市场占有率60%。根据纯碱工业协会数据显示，2019年公司氯化铵产量排名全国第二。草甘膦为国内龙头企业地位。","foundedDate":"2002-08-01","goPublicDate":"2012-07-31","companyHistory":"1.公司概况。\n　　1.1公司设立情况。\n　　四川和邦生物科技股份有限公司（原名“四川和邦股份有限公司”，于2015年7月31日更名为“四川和邦生物科技股份有限公司”，以下简称“本公司”、“公司”或“和邦生物”）前身为四川乐山和邦化工有限公司，系由四川和邦投资集团有限公司（以下简称“和邦集团”）和张丽华共同出资4,800.00万元人民币组建，于2002年8月1日经四川省乐山市工商行政管理局核准登记的有限责任公司。\n　　1.2股权变更及增资。\n　　1.2.1 2008年2月28日，根据《四川和邦股份有限公司创立大会暨第一次股东大会决议》以及《发起人协议》，本公司以截止2008年1月31日净资产折股整体变更为股份有限公司。截至2008年1月31日本公司净资产363,449,735.90元，按1.2115：1的比例折合股本30,000.00万元，差额部分63,449,735.90元转作资本公积。本次整体变更业经四川君和会计师事务所君和验字（2008）第2002号验资报告验证。整体变更后，本公司注册资本为叁亿元人民币，其中：和邦集团出资26,574.00万元，占88.58%；张丽华出资3,126.00万元，占10.42%；郑丹出资300.00万元，占1%。\n　　1.2.2 2009年3月2日，张丽华与贺正刚签订《股权转让协议》，将其所持有的本公司10.42%股权转让给自然人贺正刚。股权变更后，本公司注册资本仍为30,000.00万元，和邦集团出资26,574.00万元，占88.58%；贺正刚出资3,126.00万元，占10.42%；郑丹出资300.00万元，占1%。\n　　1.2.3 2010年5月10日，郑丹与和邦集团签订《股权转让协议》，将其所持有的本公司1%股权转让给和邦集团。股权变更后，本公司注册资本仍为30,000.00万元，和邦集团出资26,874.00万元，占89.58%；贺正刚出资3,126.00万元，占10.42%。\n　　1.2.4 2010年12月14日，本公司引进哈尔滨恒世达昌科技有限公司等八家投资者进行增资。新增投资者出资合计人民币250,000,000.00元，按5元/股的价格共折50,000,000.00股，其余200,000,000.00元作为资本公积。该项变更业经四川华信（集团）会计师事务所川华信验（2010）86号验资报告验证。\n　　1.2.5经中国证券监督管理委员会“证监许可[2012]704号”文核准，本公司于2012年7月19日首次公开发行100,000,000.00股人民币普通股（A股），发行价格为17.50元/股。发行结束后，本公司增加注册资本人民币10,000万元。\n　　1.2.6 2014年4月17日，本公司根据中国证券监督管理委员会《关于核准四川和邦股份有限公司向四川省盐业总公司发行股份购买资产的批复》（证监许可[2014]363号），以81,432.53万元的交易价格，非公开发行股份55,547,425股（发行价格为14.66元/股），购买四川省盐业总公司（以下简称“省盐公司”）持有的乐山和邦农业科技有限公司（以下简称“和邦农科”）51%股权。\n　　1.2.7 2014年7月11日，公司根据2013年度股东大会决议，以2014年4月17日股本总数505,547,425股为基数，向全体股东每股派发现金红利0.04元（含税）；同时以资本公积金转增股本，向全体股东每股转增1股。\n　　本次转增后，公司股本变更为1,011,094,850股。\n　　1.2.8 2015年5月8日，公司根据2014年第一次临时股东大会决议、中国证券监督管理委员会《关于核准四川和邦股份有限公司非公开发行股票的批复》（证监许可【2015】460号）以及修改后的章程，公司非公开发行股份92,984,676股（发行价格为15.01元/股）。本次发行后，公司股本变更为1,104,079,526股。\n　　1.2.9 2015年9月2日，公司根据2015年第三次临时股东大会决议，以2015年6月30日股本总数1,104,079,526股为基数，以资本公积金向全体股东每10股转增20股。本次转增后，公司股本变更为3,312,238,578股。\n　　1.2.10 2016年9月29日,公司根据2015年第五次临时股东大会决议、中国证券监督管理委员会2016年4月22日下发的《关于核准四川和邦生物科技股份有限公司非公开发行股票的批复》（证监许可【2016】917号）以及修改后的章程，公司非公开发行股份701,966,071股，（发行价格为5.60元/股）。本次发行后，公司股本变更为4,014,204,649股。\n　　1.2.11 2017年7月5日，公司根据2016年年度股东大会决议，以2016年12月31日股本总数4,014,204,649股为基数，以资本公积金向全体股东每10股转增10股，以未分配利润向全体股东每10股送红股2股（含税），每10股派发现金红利0.1元（含税）。本次分配后，公司股本变更为8,831,250,228股。\n　　1.3公司注册地址、组织形式、总部地址。\n　　本公司取得四川省乐山市工商行政管理局于2015年10月13日核发的《企业法人营业执照》。营业执照注册号/统一社会信用代码：91511100740039656L；住址：乐山市五通桥区牛华镇沔坝村；法定代表人：贺正刚。收起▲","shareholders":[{"organizationId":"T000035905","holderName":"四川和邦投资集团有限公司","totalShare":"24.93亿","sharePercentage":"28.23%"},{"organizationId":"00201783","holderName":"四川省盐业总公司","totalShare":"7.01亿","sharePercentage":"7.93%"},{"organizationId":"","holderName":"贺正刚","totalShare":"4.13亿","sharePercentage":"4.67%"},{"organizationId":"","holderName":"西部利得基金-兴业银行-华鑫国际信托-华鑫信托·慧智投资77号集合资金信托计划","totalShare":"3.52亿","sharePercentage":"3.99%"},{"organizationId":"","holderName":"西部利得基金-兴业银行-华鑫国际信托-华鑫信托·慧智投资78号集合资金信托计划","totalShare":"3.24亿","sharePercentage":"3.67%"},{"organizationId":"","holderName":"四川和邦生物科技股份有限公司回购专用证券账户","totalShare":"2.25亿","sharePercentage":"2.55%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1.86亿","sharePercentage":"2.10%"},{"organizationId":"","holderName":"杨联明","totalShare":"1.78亿","sharePercentage":"2.01%"},{"organizationId":"","holderName":"建信基金-兴业银行-华鑫国际信托-华鑫信托·慧智投资75号集合资金信托计划","totalShare":"1.07亿","sharePercentage":"1.21%"},{"organizationId":"","holderName":"北信瑞丰基金-宁波银行-华鑫国际信托-华鑫信托·慧智投资76号集合资金信托计划","totalShare":"7384.90万","sharePercentage":"0.84%"}],"englishDescription":"Sichuan Hebang Biotechnology Co., Ltd., formerly Sichuan Hebang Corporation Limited, is a China-based company, principally engaged in the manufacture of chemical products. The Company operates its businesses through three segments, including Agriculture segment, Chemical segment and New Materials segment. The Agriculture segment provides chemical pesticides, feed nutrients, biological pesticide machines and other biological products. The Chemical segment provides sodium carbonate, sodium chloride, salt and phosphate. The New Materials segment provides smart glass, specialty glass and carbon fibers. It distributes its products within domestic market and to overseas markets. ","englishIndustry":"Chemical Manufacturing","Price to earnings (ttm)":"32.01","Price to sales (ttm)":"2.14","Price to book (mrq)":"1.06","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"18.34","Lt debt to equity (mrq)":"1.93","Return on investment (ttm)":"3.03","Return on equity (ttm)":"2.46","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"3,402.55","Cash payments":"(2,385.50)","Cash taxes paid":"(244.99)","Changes in working capital":"(609.14)","Cash from operating activities":"162.92","Capital expenditures":"(662.54)","Other investing cash flow items, total":"(613.83)","Cash from investing activities":"(1,276.38)","Financing cash flow items":"(239.68)","Total cash dividends paid":"(71.10)","Issuance (retirement) of debt, net":"677.85","Cash from financing activities":"367.06","Foreign exchange effects":"9.29","Net change in cash":"(737.10)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"1.35","52 Week High":"1.86","52 Week Low":"1.30","Pricing date":"","10 Day Average Trading Volume":"100.18","Market Capitalization":"11,922.19","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"1,842.04","Beta":"1.03","1 Day Price Change":"1.50","13 Week Price Return (Daily)":"-0.74","26 Week Price Return (Daily)":"-8.16","5 Day Price Return (Daily)":"2.27","52 Week Price Return (Daily)":"-27.81","Year To Date Price Return (Daily)":"-8.78","Month to Date Price Return (Daily)":"2.27","Price Relative to S&P500 (4 Week)":"-5.45","Price Relative to S&P500 (13 Week)":"-14.23","Price Relative to S&P500 (26 Week)":"-17.42","Price Relative to S&P500 (52 Week)":"-36.56","Price Relative to S&P500 (YTD)":"-15.95"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.06","EPS excl. Extra Items (TTM)":"0.04","EPS Normalized (Annual)":"0.06","Revenue per Share (Annual)":"0.68","Revenue per Share (TTM)":"0.63","Book Value (Per Share Annual)":"1.27","Book Value (Per Share Quarterly)":"1.27","Tangible Book Value (Per Share Annual)":"0.93","Tangible Book Value (Per Share Quarterly)":"0.93","Cash Per Share (Per Share Annual)":"0.09","Cash Per Share (Per Share Quarterly)":"0.09","Cash Flow (Per Share Annual)":"0.13","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.00","Dividends (Per Share TTM)":"0.00","EBITD (Per Share TTM)":"0.06","EPS Basic excl. Extra Items (Annual)":"0.06","EPS Basic excl. Extra Items (TTM)":"0.04","EPS incl. Extra Items (Annual)":"0.06","EPS incl. Extra Items (TTM)":"0.04","Free Cash Flow (Per Share TTM)":"-0.08","Dividend (Per Share 5Y)":"0.01"},"Valuation":{"P/E excl. Extra Items (Annual)":"23.07","P/E excl. Extra Items (TTM)":"32.01","P/E Normalized (Annual)":"22.43","Price to sales (Annual)":"2.00","Price to sales (TTM)":"2.14","Price to Tangible Book (Annual)":"1.45","Price to Tangible Book (Quarterly)":"1.45","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"1.06","Price to Book (Quarterly)":"1.06","P/E Basic excl. Extra Items (TTM)":"34.38","P/E excl. Extra Items High (TTM)":"164.48","P/E excl. Extra Items Low (TTM)":"24.29","P/E incl. Extra Items (TTM)":"32.01","Net Debt (Interim)":"1,225.90","Net Debt (Annual)":"1,076.44","Dividend Yield (5Y)":"0.28","Dividend Yield":"--","Current Dividend Yield (TTM)":"0.00"},"Financial Strength":{"Free Cash Flow (Annual)":"-570.72","Current Ratio (Annual)":"1.25","Net Interest coverage (Annual)":"12.18","Long Term Debt/Equity (Annual)":"2.01","Payout Ratio (Annual)":"48.37","Quick Ratio (Annual)":"0.78","Total Debt/Total Equity (Annual)":"16.52","Current EV/Free Cash Flow (Annual)":"32.35","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.20","Long Term Debt/Equity (Quarterly)":"1.93","Quick Ratio (Quarterly)":"0.71","Total Debt/Total Equity (Quarterly)":"18.34","Free Cash Flow (TTM)":"-747.17","Net Interest Coverage (TTM)":"4.56","Payout Ratio (TTM)":"67.13"},"Margins":{"Gross Margin (Annual)":"22.69","Gross Margin (TTM)":"21.44","Net Profit Margin % (Annual)":"8.49","Net Profit Margin (TTM)":"6.17","Operating Margin (Annual)":"9.76","Operating Margin (TTM)":"7.22","Pretax Margin (TTM)":"7.20","Pretax Margin (Annual)":"9.78","Operating Margin (5Y)":"9.37","Pretax Margin (5Y)":"9.75","Free Operating Cash Flow/Revenue (5Y)":"-8.88","Free Operating Cash Flow/Revenue (TTM)":"-13.43","Gross Margin (5Y)":"23.11","Net Profit Margin (5Y)":"8.12"},"Management Effectiveness":{"Return on Assets (Annual)":"3.65","Return on Equity (TTM)":"2.46","Return on Average Equity (Annual)":"4.66","Return on Average equity (TTM)":"3.38","Return on Investment (Annual)":"4.45","Return on Investment (TTM)":"3.03","Return on Average Assets (5Y)":"3.00","Return on Average Equity (5Y)":"4.19","Return on Investment (5Y)":"3.75","Asset Turnover (Annual)":"0.43","Asset Turnover (TTM)":"0.40","Inventory Turnover (Annual)":"3.89","Inventory Turnover (TTM)":"3.47","Net Income/Employee (Annual)":"109,941.60","Net Income/Employee (TTM)":"71,289.34","Receivables Turnover (Annual)":"11.88","Receivables Turnover (TTM)":"8.76","Revenue/Employee (Annual)":"1,295,378.00","Revenue/Employee (TTM)":"1,156,214.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-28.31","Revenue Growth Rate (5Y)":"22.25","EPS Growth (Quarterly YoY)":"-127.71","EPS Growth (TTM YoY)":"-12.66","EPS Growth Rate (5Y)":"-10.28","Dividend Growth Rate (3Y)":"--","Revenue Growth (TTM YoY)":"-11.46","Revenue Growth (Per Share 5Y)":"15.59","Revenue Growth Rate (3Y)":"19.91","EPS Growth Rate (3Y)":"12.68","Book Value Growth Rate (Per Share 5Y)":"12.30","Tangible Book Value Total Equity CAGR (5Y)":"25.89","Capital Spending growth rate 5 year":"-1.56","EBITDA CAGR (5Y)":"21.24","EBITDA Interim CAGR (5Y)":"15.45","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"-10.73","Net Profit Margin Growth Rate (5Y)":"-22.69"},"Income Statement":{"Revenue (Annual)":"5,969.10","Revenue (TTM)":"5,564.86","EBITD (Annual)":"1,288.88","EBITD (TTM)":"516.41","Earnings Before Taxes (Annual)":"583.75","Earnings Before Taxes (TTM)":"400.79","Net Income to Common (Annual)":"516.85","Net Income to Common (TTM)":"372.44","Earnings Before Taxes Normalized (Annual)":"600.75","Net Income Available to Common Normalized (Annual)":"531.60","Diluted Normalized EPS excl. Extra Items (TTM)":"0.04"}}}